Jorge Rubio-Gracia 1,2 , Ignacio Giménez-López 2,3,4 , Vanesa Garcés-Horna 1,2 , Daniel López-Delgado 1 , Jose Luis Sierra-Monzón 2,5 , Luis Martínez-Lostao 2,4,6 , Claudia Josa-Laorden 1,2 , Fernando Ruiz-Laiglesia 1,2 , Juan Ignacio Pérez-Calvo 1,2,3,4 , Silvia Crespo-Aznarez 1 , Javier García-Lafuente 1 , Natasha Peña Fresneda 2,4 , Beatriz Amores Arriaga 1,2 , Borja Gracia-Tello 1,2,6 , Marta Sánchez-Marteles 1,2 Show Affiliations »
Abstract
BACKGROUND: Lung ultrasound (LUS) is feasible for assessing lung injury caused by COVID-19. However, the prognostic meaning and time-line changes of lung injury assessed by LUS in COVID-19 hospitalised patients, is unknown. METHODS: Prospective cohort study designed to analyse prognostic value of LUS in COVID-19 patients by using a quantitative scale (LUZ-score) during the first 72 h after admission. Primary endpoint was in-hospital death and/or admission to the intensive care unit. Total length of hospital stay, increase of oxygen flow or escalate medical treatment during the first 72 h, were secondary endpoints. RESULTS: 130 patients were included in the final analysis; mean age was 56.7±13.5 years. Time since the beginning of symptoms until admission was 6 days (4-9). Lung injury assessed by LUZ-score did not differ during the first 72 h (21 points [16-26] at admission versus 20 points [16-27] at 72 h; p=0.183). In univariable logistic regression analysis estimated PaO2/FiO2 (HR 0.99 [0.98-0.99]; p=0.027) and LUZ-score>22 points (5.45 (1.42-20.90); p=0.013) were predictors for the primary endpoint. CONCLUSIONS: LUZ-score is an easy, simple and fast point of care ultrasound tool to identify patients with severe lung injury due to COVID-19, upon admission. Baseline score is predictive of severity along the whole period of hospitalisation. The score facilitates early implementation or intensification of treatment for COVID-19 infection. LUZ-score may be combined with clinical variables (as estimated PAFI) to further refine risk stratification. ©The authors 2021.
BACKGROUND: Lung ultrasound (LUS ) is feasible for assessing lung injury caused by COVID-19 . However, the prognostic meaning and time-line changes of lung injury assessed by LUS in COVID-19 hospitalised patients , is unknown. METHODS: Prospective cohort study designed to analyse prognostic value of LUS in COVID-19 patients by using a quantitative scale (LUZ-score) during the first 72 h after admission. Primary endpoint was in-hospital death and/or admission to the intensive care unit. Total length of hospital stay, increase of oxygen flow or escalate medical treatment during the first 72 h, were secondary endpoints. RESULTS: 130 patients were included in the final analysis; mean age was 56.7±13.5 years. Time since the beginning of symptoms until admission was 6 days (4-9). Lung injury assessed by LUZ-score did not differ during the first 72 h (21 points [16-26] at admission versus 20 points [16-27] at 72 h; p=0.183). In univariable logistic regression analysis estimated PaO2/FiO2 (HR 0.99 [0.98-0.99]; p=0.027) and LUZ-score>22 points (5.45 (1.42-20.90); p=0.013) were predictors for the primary endpoint. CONCLUSIONS: LUZ-score is an easy, simple and fast point of care ultrasound tool to identify patients with severe lung injury due to COVID-19 , upon admission. Baseline score is predictive of severity along the whole period of hospitalisation. The score facilitates early implementation or intensification of treatment for COVID-19 infection . LUZ-score may be combined with clinical variables (as estimated PAFI) to further refine risk stratification. ©The authors 2021.
Entities: Chemical
Disease
Gene
Species
Year: 2021
PMID： 33574074 DOI： 10.1183/13993003.04283-2020
Source DB: PubMed Journal: Eur Respir J ISSN： 0903-1936 Impact factor: 16.671